Peptide News Digest

#Enhertu

2 stories

Regulatory · View digest

NICE Final Draft Guidance Recommends Enhertu for HER2-Low Advanced Breast Cancer, Reversing an Earlier Rejection

NICE published final draft guidance on Thursday, September 17, 2026 recommending Enhertu (trastuzumab deruxtecan, from Daiichi Sankyo and AstraZeneca) for adults with HER2-low advanced or metastatic breast cancer whose disease has progressed after treatment, a group NICE estimated at about 1,000 people. NICE had previously rejected the drug for this use on cost-effectiveness grounds. It said the reversal followed an agreed commercial solution, the higher cost-effectiveness thresholds it began using in April 2026, and a new method for assessing quality of life published on August 27, 2026. The guidance is open to appeal until 5pm on October 7, 2026.

Research · View digest

Avacta AVA6103 Peptide-Drug Conjugate Shows 3x Tumor Selectivity vs Enhertu in Preclinical Data

Avacta Therapeutics presented April 21 data at AACR 2026 showing its FAP-enabled peptide-drug conjugate AVA6103, which delivers exatecan via the pre|CISION® platform, achieved a Tumor Selectivity Index three times higher than marketed ADC Enhertu in preclinical models, with tumor Cmax more than one log higher. AVA6103 entered the Phase 1 FOCUS-01 trial (NCT07454642) in March 2026 with initial clinical readout expected later this year.